Homologous Recombination Deficiency (HRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Homologous recombination deficiency (HRD) is a cellular phenotype characterized by the inability to repair double-strand DNA effectively breaks through the homologous recombination repair (HRR) pathway. This condition can arise from mutations in BRCA1, BRCA2, and other HRR pathway genes. Various tumor types, including breast, ovarian, prostate, and pancreatic cancers, have been linked to deficiencies in the HRR pathway. Cells lacking functional HRR must rely on alternative, less precise DNA repair pathways. These pathways can lead to widespread genomic alterations, including insertions, deletions, copy number changes, and structural rearrangements. Molecular techniques can detect these genomic scars, which are indicative of HRD. Alterations in these genes have been identified as potential “causes” of HRD, encompassing genetic and epigenetic events. HRR is a vital DNA repair mechanism that corrects various types of DNA damage, particularly double-strand breaks and interstrand cross-links, using the sister chromatid as a repair template. While other genes in the HRR pathway, such as ATM, PALB2, and RAD51, have also been linked to HRD, their associations with different cancers are less consistent than BRCA1/2. The FDA has approved multiple companion or complementary diagnostics. These diagnostics aim to aid in selecting appropriate PARP inhibitor (PARPi) treatments based on the HR status of patients. Among these diagnostics are FoundationOne CDx and the Myriad myChoice CDx test, which evaluate chromosomal instability. They help identify ovarian cancer patients who could benefit from an FDA-approved therapy. These assays take into account both the causes and consequences of HRR impairment, setting them apart from other FDA-approved tests like BRACAnalysis CDx, FoundationOne Liquid CDx, and FoundationOne CDx, which primarily focus on detecting potential causes of HRR impairment. Lynparza (olaparib), Zejula (niraparib), and Rubraca (rucaparib), these PARPi drugs utilize HRD as biomarkers for patient selection in both initial and recurrent cases of epithelial ovarian, fallopian tube, or primary peritoneal cancers.

Thelansis’s “Homologous Recombination Deficiency (HRD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Homologous Recombination Deficiency (HRD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Homologous Recombination Deficiency (HRD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Homologous Recombination Deficiency (HRD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Homologous Recombination Deficiency (HRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033